Selective delivery of PEGylated compounds to tumor cells by anti-PEG hybrid antibodies

Molecular Cancer Therapeutics

Volumn 14, Issue 6, 2015, Pages 1317-1326

  Tung, Hsin Yi ^a,b   Su, Yu Cheng ^b   Chen, Bing Mae ^b   Burnouf, Pierre Alain ^a,b   Huang, Wei Chiao ^b   Chuang, Kuo Hsiang ^c   Yan, Yu Ting ^b   Cheng, Tian Lu ^d   Roffler, Steve R ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIBODY; COMPLEMENT COMPONENT C3B RECEPTOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MACROGOL; UNCLASSIFIED DRUG; ANTIBODY; CD19 ANTIGEN; LIPOSOME; MACROGOL DERIVATIVE; NANOPARTICLE; PROTEIN; PROTEIN BINDING;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BREAST ADENOCARCINOMA; BURKITT LYMPHOMA CELL LINE; CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURFACE; CELLULAR DISTRIBUTION; CLINICAL EFFECTIVENESS; COLORECTAL CANCER CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG BINDING SITE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PURIFICATION; DRUG TARGETING; ENDOCYTOSIS; GENE OVEREXPRESSION; HEAVY CHAIN; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INTERNALIZATION; LIGHT CHAIN; MOLECULAR STABILITY; MOLECULAR WEIGHT; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; BINDING COMPETITION; CELL SURVIVAL; CONFOCAL MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEK293 CELL LINE; HT 29 CELL LINE; MCF 7 CELL LINE; METABOLISM; NEOPLASM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANTIBODIES; ANTIGENS, CD19; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; ENDOCYTOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEK293 CELLS; HT29 CELLS; HUMANS; LIPOSOMES; MCF-7 CELLS; MICROSCOPY, CONFOCAL; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; POLYETHYLENE GLYCOLS; PROTEIN BINDING; PROTEINS; RECEPTOR, ERBB-2;

EID: 84942091825     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0151     Document Type: Article

References (52)

1. Brinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1 (27-35) peptide: implications for peptide vaccines. Int J Cancer 1999;83:326-34.
2. Cantin AM, Woods DE, Cloutier D, Dufour EK, Leduc R. Polyethylene glycol conjugation at Cys232 prolongs the half-life of alpha1 proteinase inhibitor. Am J Respir Cell Mol Biol 2002;27:659-65.
3. Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 1992;89:1643-51.
4. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991;88:11460-4.
5. Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs 2009;14:363-80.
6. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998;95:4607-12.
7. Brand FX, Ravanel N, Gauchez AS, Pasquier D, Payan R, Fagret D, et al. Prospect for anti-her2 receptor therapy in breast cancer. Anticancer Res 2006;26:715-22.
8. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66:6732-40.
9. Boeckler C, Frisch B, Muller S, Schuber F. Immunogenicity of new heterobifunctional cross-linking reagents used in the conjugation of synthetic peptides to liposomes. J Immunol Methods 1996;191:1-10.
10. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114-24.
11. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, et al. A twoinone antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011;20:472-86.
12. Schlenzka J, Moehler TM, Kipriyanov SM, Kornacker M, Benner A, Bahre A, et al. Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinicalmodel of human B cell lymphoma. Anticancer Drugs 2004;15:915-9.
13. Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci U S A 2011;108:8194-9.
14. Cheng TL, Cheng CM, Chen BM, Tsao DA, Chuang KH, Hsiao SW, et al. Monoclonal antibody-based quantitation of poly (ethylene glycol)-derivatized proteins, liposomes, and nanoparticles. Bioconjug Chem 2005;16:1225-31.
15. Su YC, Chen BM, Chuang KH, Cheng TL, Roffler SR. Sensitive quantification of PEGylated compounds by second-generation anti-poly (ethylene glycol) monoclonal antibodies. Bioconjug Chem 2010;21:1264-70.
16. Chuang KH, Wang HE, Cheng TC, Tzou SC, Tseng WL, Hung WC, et al. Development of a universal anti-polyethylene glycol reporter gene for noninvasive imaging of PEGylated probes. J Nucl Med 2010;51:933-41.
17. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996;9:617-21.
18. Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997;270:26-35.
19. Rydzanicz R, Zhao XS, Johnson PE. Assembly PCR oligo maker: a tool for designing oligodeoxynucleotides for constructing long DNA molecules for RNA production. Nucleic Acids Res 2005;33:W521-5.
20. Chen KC, Cheng TL, Leu YL, Prijovich ZM, Chuang CH, Chen BM, et al. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes. Cancer Gene Ther 2007;14:187-200.
21. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, Van Roey M, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005;23:584-90.
22. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 2004;279:53907-14.
23. Mcdonagh C, Cerveny CG, Benjamin D, Carter P, Gerber H, Francisco Linventor; Seattle Genetics, Inc., assignee. CD19 binding agents and uses thereof. United States patent US 8242252 2012 Aug. 14.
24. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011;108:11187-92.
25. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem 1959;234:466-8.
26. Kao CH, Wang JY, Chuang KH, Chuang CH, Cheng TC, Hsieh YC, et al. One-step mixingwith humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. Biomaterials 2014;35:9930-40.
27. Chuang KH, Tzou SC, Cheng TC, Kao CH, Tseng WL, Shiea J, et al. Measurement of poly (ethylene glycol) by cell-based anti-poly (ethylene glycol) ELISA. Anal Chem 2010;82:2355-62.
28. Carmichael J, De Graff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
29. Jasinska J, Wagner S, Radauer C, Sedivy R, Brodowicz T, Wiltschke C, et al. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int J Cancer 2003;107:976-83.
30. Cheng TL, Wu PY, Wu MF, Chern JW, Roffler SR. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug Chem 1999;10:520-8.
31. Brissault B, Kichler A, Leborgne C, Danos O, Cheradame H, Gau J, et al. Synthesis, characterization, and gene transfer application of poly (ethylene glycol-b-ethylenimine) with high molar mass polyamine block. Biomacromolecules 2006;7:2863-70.
32. Hatakeyama H, Akita H, Harashima H. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull 2013;36:892-9.
33. Dubey PK, Mishra V, Jain S, Mahor S, Vyas SP. Liposomes modified with cyclic RGD peptide for tumor targeting. J Drug Target 2004;12:257-64.
34. Chaudhury A, Das S. Folate receptor targeted liposomes encapsulating anticancer drugs. Curr Pharm Biotechnol 2015;16:333-43.
35. Aravind A, Jeyamohan P, Nair R, Veeranarayanan S, Nagaoka Y, Yoshida Y, et al. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng 2012;109:2920-31.
36. Mendonca LS, Firmino F, Moreira JN, Pedroso de Lima MC, Simoes S. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem 2010;21:157-68.
37. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, et al. Cantuzumabmertansine, amaytansinoid immunoconjugate directed to the Can Ag antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21:211-22.
38. Lehtinen J, Magarkar A, Stepniewski M, Hakola S, Bergman M, Rog T, et al. Analysis of cause of failure of new targeting peptide in PEGylated liposome: molecular modeling as rational design tool for nanomedicine. Eur J Pharm Sci 2012;46:121-30.
39. Rauscher A, Frindel M, Maurel C, Maillasson M, Le Saec P, Rajerison H, et al. Influence of pegylation and hapten location at the surface of radiolabelled liposomes on tumour immunotargeting using bispecific antibody. Nucl Med Biol 2014;41 Suppl:e66-74.
40. Botosoa EP, Maillasson M, Mougin-Degraef M, Remaud-Le Saec P, Gestin JF, Jacques Y, et al. Antibody-hapten recognition at the surface of functionalized liposomes studied by SPR: steric hindrance of pegylated phospholipids in stealth liposomes prepared for targeted radionuclide delivery. J Drug Deliv 2011;2011:368535.
41. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 1998;95:652-6.
42. Flieger D, Spengler U, Beier I, Kleinschmidt R, Hoff A, Varvenne M, et al. Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines. Hybridoma 1999;18:63-8.
43. Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003;55:1293-302.
44. Matthews SJ, McCoy C. Peginterferon alfa-2a: a review of approved and investigational uses. Clin Ther 2004;26:991-1025.
45. Luxon BA, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 2002;24:1363-83.
46. Stathopoulos GP, Dimou E, Stathopoulos J, Xynotroulas J. Therapeutic administration of pegfilgrastim instead of prophylactic use. Anticancer Res 2005;25:2445-8.
47. Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008;68:1139-56.
48. Uchida S, Itaka K, Chen Q, Osada K, Ishii T, Shibata MA, et al. PEGylated polyplex with optimized PEG shielding enhances gene introduction in lungs by minimizing inflammatory responses. Mol Ther 2012;20:1196-203.
49. Allen TM. Liposomes. Opportunities in drug delivery. Drugs 1997;54 Suppl 4:8-14.
50. Fassas A, Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 2005;46:795-802.
51. Kovtun O, Arzeta-Ferrer X, Rosenthal SJ. Quantum dot approaches for target-based drug screening and multiplexed active biosensing. Nanoscale 2013;5:12072-81.
52. Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J 2010;5:113-28.